PharmaCyte shareholders approve reverse stock split and increase equity plan shares by 2M at annual meeting

PharmaCyte Biotech, Inc.

Approved reverse stock split at ratio 1:1.1 to 1:100; 5,067,304 for, 2,280,497 against.
Approved amendment to 2022 Equity Incentive Plan increasing share reserve by 2,000,000 shares.
Elected five directors (Silverman, Schechter, Abecassis, Weinstein, Walker) to hold office until 2027 annual meeting.
Ratified CBIZ CPAs P.C. as independent auditor for FY ending April 30, 2026; 6,837,442 for votes.
Non-binding advisory approval of executive compensation received majority support (3,306,883 for votes).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.